Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash & Current Investments: 2014-2025

Historic Cash & Current Investments for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to $135.6 million.

  • AC Immune's Cash & Current Investments fell 25.60% to $135.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $297.9 million, marking a year-over-year decrease of 51.34%. This contributed to the annual value of $135.6 million for FY2025, which is N/A change from last year.
  • According to the latest figures from Q3 2025, AC Immune's Cash & Current Investments is $135.6 million, which was up 88,196.78% from $153,565 recorded in Q2 2025.
  • AC Immune's Cash & Current Investments' 5-year high stood at $72.1 billion during Q1 2021, with a 5-year trough of $153,565 in Q2 2025.
  • Moreover, its 3-year median value for Cash & Current Investments was $116.2 million (2023), whereas its average is $108.2 million.
  • As far as peak fluctuations go, AC Immune's Cash & Current Investments surged by 24,985.21% in 2021, and later crashed by 99.92% in 2025.
  • Over the past 5 years, AC Immune's Cash & Current Investments (Quarterly) stood at $215.0 million in 2021, then plummeted by 40.81% to $127.2 million in 2022, then declined by 8.70% to $116.2 million in 2023, then plummeted by 99.84% to $188,909 in 2024, then decreased by 25.60% to $135.6 million in 2025.
  • Its Cash & Current Investments stands at $135.6 million for Q3 2025, versus $153,565 for Q2 2025 and $162.0 million for Q1 2025.